What was studied?
Sixty adults with abdominal obesity and reduced growth-hormone secretion entered a randomized, double-blind, placebo-controlled study lasting 12 months. Researchers measured abdominal fat with imaging and assessed vascular and metabolic risk markers.
What did the researchers report?
The investigators reported reduced visceral fat and favorable changes in some risk markers, including carotid intima-media thickness. Subcutaneous abdominal fat did not show a significant treatment effect in the reported analysis.
What are the limits?
This selected population and small sample limit broader conclusions. A change in a risk marker is not proof of fewer heart attacks or strokes. The results do not establish a general obesity treatment recommendation, long-term clinical safety or efficacy of other supply materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.